10-Q · July 9, 2026
Byrna Technologies reported significant financial challenges in Q2 2026, with total revenue of $16.4 million, a dramatic 42.5% decline from $28.5 million in the same quarter last year. Gross profit also plummeted to…
Earnings analysis · 10-Q
BYRN earnings analysis
Filed October 8, 2026 · Our reading of the company's report
The latest report
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so current-period revenue, margins, EPS, cash flow, and quantitative outlook cannot be…
Read full summary
The supplied 10-Q text does not include the income statement, balance sheet, cash-flow statement, segment results, or MD&A, so current-period revenue, margins, EPS, cash flow, and quantitative outlook cannot be assessed. The principal update is a new material regulatory issue involving Fox Labs products containing prohibited trichloroethylene, identified in September 2026, with shipments and sales suspended. Byrna disclosed the matter to the EPA as of October 6, 2026 and warned of possible penalties, remediation costs, lost revenue, inventory write-downs, and reputational effects.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Disclosure controls remained effective
Management concluded with reasonable assurance that disclosure controls and procedures were effective as of August 31, 2026.
-
No material control changes reported
The company reported no changes during the third quarter of 2026 that materially affected, or were reasonably likely to materially affect, internal control over financial reporting.
-
Buyback program expired without Q3 repurchases
No common shares were repurchased during the three months ended August 31, 2026, and the $10 million stock buyback program expired on July 31, 2026.
What to watch
-
New prohibited-solvent regulatory exposure
In September 2026, Byrna determined that certain Fox Labs defense sprays contained trichloroethylene, whose processing and distribution for consumer use has been prohibited under an EPA rule since June 2025. The company suspended shipments and directed dealers and distributors to suspend sales.
-
Potential penalties and remediation costs
As of October 6, 2026, Byrna voluntarily disclosed the matter to the EPA and intends to file a voluntary disclosure report with the CPSC. Potential consequences include civil penalties, claims, inventory write-downs, and costs to reformulate, relabel, replace, or dispose of products.
-
Product suspension and filler recovery risk
The affected Fox Labs product lines may lose revenue while being reformulated, and Byrna may be unable to recover costs from its third-party contract filler. The company stated that the outcome, cost, and duration cannot be predicted and could materially affect results and financial condition.
Management's outlook
The supplied 10-Q excerpt does not include financial statements, MD&A, or quantitative outlook. No numeric revenue or EPS guidance is provided in the available filing text.
Earlier filings 2
10-Q · April 9, 2026
Byrna reported revenue of $29.05M and gross profit of $17.40M for the quarter ended February 28, 2026, up versus the prior-year quarter (revenue $26.19M). Gross margin remained steady at ~59.9% while operating income…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.